The initiative will integrate a 1726 nm laser for acne treatment into dermatology curricula to provide hands-on training and support new research.
Cutera Inc, a provider of aesthetic and dermatological solutions, has launched a new residency program designed to expand access to its AviClear 1726 nm laser system within dermatology training programs across North America. The laser is US Food and Drug Administration-cleared for the long-term treatment of mild, moderate, and severe acne.
The program aims to support acne care innovation, research, and education by integrating the technology into the clinical curriculum of academic institutions. By incorporating the laser directly into residency training, the company intends to equip future dermatologists with experience using the device.
“Our goal is to empower the next generation of dermatologists through education and innovation,” says Taylor Harris, CEO of Cutera Inc, in a release. “By introducing AviClear into residency programs, we’re advancing clinical training while reinforcing our commitment to pioneering solutions that shape the future of dermatology and improve lives.”
The program establishes a 24-month partnership that includes technology integration and structured clinical training. It also creates opportunities for collaboration on publications, research, and exploration of new clinical indications. The company notes that the program creates pathways to its broader technology portfolio, ensuring participants gain exposure to a range of innovations.
“Residents will now have early access to cutting-edge technology like AviClear, giving them hands-on experience with the future of acne care,” says Ashish C Bhatia, MD, FAAD, co-director of dermatologic, laser, and cosmetic surgery at Oak Dermatology, in a release. “At the same time, this partnership opens the door to exciting new research opportunities into sebaceous-based conditions such as sebaceous hyperplasia and hidradenitis suppurativa, expanding what’s possible in dermatologic care.”
Cutera’s clinical research team is actively studying the AviClear device for a range of new indications tied to the sebaceous gland, including sebaceous hyperplasia, hidradenitis suppurativa, oily skin, and pore size.
Cutera is currently accepting applications from universities and programs interested in joining the Cutera Residency Program. Interested parties can apply and learn more by emailing [email protected].
ID 168032621 | Acne Face © Dmytro Dudchenko | Dreamstime.com
